Orchestra BioMed (OBIO) Insider Prosper Buys 34,653 Shares

Insider Buying and Selling at Orchestra BioMed Holdings, Inc.

Mack John Prosper picked up 34,653 shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) on June 23, 2026. This purchase arrived as part of a larger, coordinated round of buying by several members of the company's leadership team on the exact same day, signaling alignment among key decision-makers.

Coordinated Buying Across Leadership

The transaction on June 23, 2026, included purchases from multiple other insiders. Jason Aryeh acquired 42,553 shares, while Chris Cleary also picked up 42,553 shares. David Pacitti made two separate purchases, adding 21,277 shares in one transaction and another 17,327 shares. Pamela Ann Connealy rounded out the group by purchasing 17,327 shares, bringing substantial collective buying volume to the stock on a single day.

Stock Valuation and Trading Range

The company shares recently traded around $3.98, sitting below its 50-day moving average of $4.72 and above its 52-week low of $2.20. The biotechnology firm holds a market capitalization of $375.66 million, operating with a forward P/E ratio that has no meaningful positive multiple due to current negative earnings.

Recent Financial Results

For its financial background, the firm posted annual revenue of $31.98 million with a revenue growth rate of -0.89%. The net profit margin stands at -1,846.04% alongside a return on equity of -3.97%. Market participants can look ahead to the next earnings report scheduled for November 5, 2026, for updated financial metrics.

Wall Street Analyst Views

Analyst updates have kept a generally positive outlook on the company through recent months. On August 11, 2026, Piper Sandler reiterated its overweight rating on the stock with a $10.00 price target, moving up from $9.00. Later, on September 10, 2026, BTIG upgraded the stock to a buy with a $10.00 price target. Most recently on September 15, 2026, B. Riley Securities maintained its buy rating while raising its price target to $11.00 from $10.00. Across the broader analyst community, the stock carries a strong buy recommendation and a mean target price of $12.14.

Biomedical Development in New Hope

Orchestra BioMed Holdings, Inc. is a biomedical company based in New Hope, Pennsylvania, focused on therapeutic candidates for cardiovascular and vascular diseases. The firm works alongside major medical device partners to advance its clinical pipeline, making insider capital allocation decisions a closely watched signal for market observers.

What to Watch at OBIO

Investors will monitor upcoming SEC filings to track whether further insider accumulation continues following the June purchases. The upcoming November 5 earnings release will provide the next major checkpoint for operational updates.